MyFinsight
Home
Blog
About
Proceeds from issuance of
common stock and...
$714,818K
Proceeds from issuance of
common stock under...
$20,624K
Net cash provided by
financing activities
$672,569K
(115660.59%↑ Y/Y)
Canceled cashflow
$62,873K
Net change in cash,
cash equivalents and...
$187,730K
(1079.80%↑ Y/Y)
Canceled cashflow
$484,839K
something is missing
-$62,778K
Payment of transaction
costs
$95K
Sales and maturities
of marketable...
$73,102K
(76.84%↑ Y/Y)
Purchase of property and
equipment
-$20K
(-103.21%↓ Y/Y)
Stock-based compensation
$16,892K
(157.11%↑ Y/Y)
Accrued expenses and
other liabilities
$5,901K
(419.45%↑ Y/Y)
Noncash operating lease
expense
$988K
(-2.95%↓ Y/Y)
Depreciation
$425K
(-32.00%↓ Y/Y)
Net cash (used in)
provided by investing...
-$445,973K
(-2758.08%↓ Y/Y)
Net cash used in
operating activities
-$38,866K
(-6.43%↓ Y/Y)
Canceled cashflow
$73,122K
Canceled cashflow
$24,206K
Purchases of marketable
securities
$519,095K
(2068.68%↑ Y/Y)
Net loss
-$55,342K
(-42.44%↓ Y/Y)
Prepaid expenses and
other current assets
$5,192K
(367.75%↑ Y/Y)
Accretion on marketable
securities
-$945K
(-30.89%↓ Y/Y)
Operating lease
liabilities
-$797K
(2.09%↑ Y/Y)
Accounts payable
-$759K
(13.75%↑ Y/Y)
Other long-term
assets
$19K
(-93.81%↓ Y/Y)
Other, net
$18K
(1700.00%↑ Y/Y)
Back
Back
Cash Flow
TNGX_BIG
Tango Therapeutics, Inc. (TNGX)
TNGX_BIG
Tango Therapeutics, Inc. (TNGX)
source: myfinsight.com